evipedia.ai
← Back

Essential Amino Acids for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Essential amino acids, nine protein building blocks the body cannot make, are sold as dietary supplements to preserve muscle. Evidence most consistently shows less muscle wasting during bed rest or after joint replacement. Older adults gain little strength, mostly with exercise; added muscle has not been shown with ample protein intake. Long-term safety is unresolved; certain inherited metabolic disorders, advanced kidney disease, some antidepressants and Parkinson's medication raise clearer concerns. (Full Review)

Protocol

Standard daily dose (older adults)
15 g/day EAAs
Between meals, as 7.5 g twice daily or one 15 g dose; about 15 g per dose approaches the maximal muscle protein synthesis response
Leucine share
About 41% leucine
For older adults, overcame aging muscle's blunted response to amino acids where a mix with 26% leucine, patterned on whey protein, did not; emphasized alongside resistance exercise
Perioperative regimens
20 g twice daily
From 1 week before to 6 weeks after knee replacement, or 9 g/day from 1 week before to 2 weeks after
Time to effect
Muscle sparing after surgery
2–6 weeks
Seen in two knee replacement trials
Lean mass in older adults
About 12 weeks
Gains at week 12 were no longer significant at week 16 in one trial

Benefits

Contraindications
  • Phenylketonuria
  • Maple syrup urine disease
  • Prior eosinophilia-myalgia syndrome after tryptophan
  • Chronic kidney disease stages 3–5 not on dialysis under a prescribed low-protein diet (0.55–0.60 g/kg/day), unless the EAA product is part of that prescription
  • Amyotrophic lateral sclerosis, for BCAA-rich products
  • Breastfeeding, for tryptophan-containing products
    •
Key Interactions
  • MAO inhibitors (phenelzine, tranylcypromine): tryptophan-containing blends to be avoided
  • SSRIs and SNRIs (citalopram, fluoxetine): tryptophan can trigger serotonin syndrome
  • Levodopa (carbidopa-levodopa): leucine, isoleucine or phenylalanine reversed its motor benefit
  • Glucose-lowering drugs (insulin, sulfonylureas): could add to low-blood-sugar risk (theoretical)
  • Phenothiazines and benzodiazepines (chlorpromazine, diazepam): tryptophan's drowsiness adds to sedation
  • mTOR inhibitors (rapamycin/sirolimus, everolimus): EAAs may offset intended effects (theoretical)
  • Over-the-counter dextromethorphan: with tryptophan, may raise serotonin syndrome risk (theoretical)
  • Additive anabolic supplements (whey protein, creatine): effects on muscle protein supply add up (theoretical)
  • Serotonergic supplements (5-HTP; St John's wort): additive serotonergic load with tryptophan (theoretical)
  • Fasting and protein-restriction protocols: EAAs end the fasted metabolic state (theoretical)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Insulin Resistance and Type 2 Diabetes; Pro-Aging Growth Signaling in Midlife; Kidney Strain in Existing Kidney Disease; Raised Homocysteine from Methionine; Hyperammonemia at Very High Leucine Intakes; Eosinophilia-Myalgia Syndrome from Contaminated Tryptophan; Drowsiness and Nausea from Tryptophan; Suicidal Thoughts During Tryptophan Treatment; Gastrointestinal Discomfort; Excess Mortality with High-Dose BCAAs in Amyotrophic Lateral Sclerosis
    •
  • Speculative: Shorter Lifespan with Chronic High BCAA Intake
    •

Monitoring

Marker Target Why
eGFR No established target; track change from own baseline Safety check: a decline stops or reduces use
BUN 7–20 mg/dL Safety check: tracks nitrogen load
Fasting glucose 70–99 mg/dL Safety check: a rise flags the diabetes signal
HbA1c 4.0–5.6% Safety check: 3-month glucose trend
Fasting insulin / HOMA-IR No established target; track change from own baseline Safety check: rising insulin resistance changes use
Triglycerides <100 mg/dL May fall with EAAs
Homocysteine 5–15 µmol/L Safety check: methionine-driven rise
Serum albumin 3.5–5.0 g/dL Declined less with perioperative EAAs
Appendicular lean mass (DXA) No established target; track change from own baseline Primary muscle outcome
Grip strength No established target; track change from own baseline Strength outcome
Cystatin C Not specified in the ER Paired with eGFR
Vitamin B12 Not specified in the ER Paired with homocysteine
Folate Not specified in the ER Paired with homocysteine

Cadence: Baseline before starting; laboratory retesting at 3 months, then every 6–12 months during continued use; muscle measures repeated at 3–6 months. Perioperative courses need only the baseline panel and a kidney function check after the course.

Qualitative Assessment

  • Recovery between training sessions and after illness or surgery
  • Ease of daily tasks such as climbing stairs or rising from a chair
  • Energy levels and appetite, including whether supplements displace meals
  • Gastrointestinal tolerance (bloating, nausea, loose stools)
  • Daytime drowsiness or sleep changes with tryptophan-containing blends
  • Agitation, tremor or restlessness in people taking serotonergic medications
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.